Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort study

• Main Authors: Siyuan Chen (Author), Tao Li (Author), Wenyu Yang (Author), Ting Wang (Author), Yuhui Qin (Author), Zhijuan Du (Author), Yanan Li (Author), Pengfei Cui (Author), Yi Hu (Author), Zhefeng Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The purpose of this study was to assess the comparative efficacy of six programmed cell death-1 inhibitors (nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, and camrelizumab) that have been used as first-line therapy for Chinese patients with advanced non-small cell lung cancer (NSCL...